Table 3
From the following article
Brazilian health biotech—fostering crosstalk between public and private sectors
Rahim Rezaie, Sarah E Frew, Stephen M Sammut, Maya R Maliakkal, Abdallah S Daar & Peter A Singer
Nature Biotechnology 26, 627 - 644 (2008)
doi:10.1038/nbt0608-627
Table 3. Alliances/collaborations between companies interviewed and domestic organizations
| Company | Brazilian alliances (past and/or present) and their objectives (where stated) |
|---|---|
| Aché Laboratórios Farmacêuticos | Joint venture with União Química and Biolab to form COINFAR. Partnerships with the UNICAMP for synthetic compound for type 2 diabetes, with University of Santa Catarina for pharmacological and toxicological studies and with the University of São Paulo for studies in a variety of areas. |
| BIOCANCER | Partnerships with various hospitals, the Ecoar Image Centre and the Federal University of Minas Gerais (all based in Belo Horizonte) for conducting clinical research. |
| Biogene | Partnership with FK Biotecnologia for developing human visceral leishmaniasis diagnostic kit. Partnership with Federal University of Campina Grande (Campina Grande) for new brucellosis and toxoplasmosis diagnostic tests. Collaborative and co-development efforts with the Federal University of Pernambuco (Recife). |
| Biolab Sanus Farmacêutica | Involved in two joint ventures; one with Aché and União Química called COINFAR, which focuses on radical innovations, and the other with Eurofarma and União Química called Incrementha (São Paulo), which is focused on incremental and process innovations. Collaborations with Institute of Energy and Nuclear Research (São Paulo) for Bandgel bandage that enhances treatment of burns and wounds; Federal University of the State of São Paulo and Paulista School of Medicine (São Paulo) for lead compounds in phase 1 and 2; University of São Paulo Faculty of Pharmaceutics and Biochemistry at the University of São Paulo for bioequivalence and bioavailability tests of new pharmaceutical formulations; Centre of Research and Support in Human Reproduction (Salvador) for co-development of Lovelle (desogestrel combined with ethinyl estradiol), a hormonal vaginal contraceptive pill. |
| BIOMM | Collaborations with University of Brasilia and University of São Paulo for development of bacterial and mammalian expression systems. |
| COINFAR | Collaboration with Centre for Applied Toxicology at Butantan Institute (São Paulo) for production of EVASINS (endogenous vasopeptidase inhibitors), venom-based hypertension drug and other toxin-based drugs for blood clotting, cardiovascular system, pain perception and immune suppression in preclinical trials. Investment in an early-stage drug development facility with University of Minas Gerais for cardiovascular disease and cancer. Collaborations with the University of Santa Catarina (Florianópolis), University of São Paulo, University of Brasilia, University of Campinas for efficacy and safety testing of various molecules. |
| Cryopraxis Criobiologia | Collaborations with Federal University of Rio de Janeiro and several hospitals for clinical trials using standardized mononuclear stem cell formulations and Universidade Federal Fluminense (Niterói) for experimental research on cellular differentiation in animal models. |
| Eurofarma Laboratórios | Partner in Incrementha, a joint venture with Biolab and União Química dedicated to development of new products and technologies using nanoparticles and solubilization of insoluble molecules. Collaborations with Inova Biotecnologia Saude Animal (Juatuba); the State University of São Paulo (UNESP) for development of a topical antifungicide and antibiotic, with UNIVALI (Universidade do Vale do Itajaí, Itajaí) in Santa Caterina for an oral analgesic, with Federal University of São Paulo (USP), UNICAMP (State University of Campinas). Working with some Brazilian universities to develop new herbal medicines using Brazilian biodiversity. |
| FK Biotecnologia | Distributing products through LIFEMED. Collaborations with a large Brazilian firm (not disclosed) and Nanocore (Campinas) for new product development; with Federal University of Rio Grande do Sul (Porto Alegre) for development of biotech products; with the Center for Tumoral Immunology, Immunotherapy and Immunodiagnostics (Porto Alegre), Hopital de Clínicas de Porto Alegre for a clinical trial of a prostate cancer vaccine, the Oswaldo Cruz Foundation (Rio de Janeiro) to develop public health assays, including tests for dengue, leishmaniasis, leptosporosis, HIV and toxoplasmosis. |
| Hebron Farmacêutica Pesquisa, Desenvolvimento e Inovação Tecnológica | Collaboration with the Antibiotics Institute from UFPE (Federal University of Pernambuco) for development of two of its drugs (Florax, a suspension of Saccharomyces cerevisiae; and Giamebil, a hydroalcoholic extract from the Mentha crispa plant); with Oncology Department of São Paulo School of Medicine and São Paulo Federal University for development of Imunoglucan; with Pharmacy Laboratory at UFPE for development of Kronel; and with UNICAMP to develop Prostokos (mesoprostol) as a labor inducer. |
| Katal Biotecnológica | Partnerships with the Federal University of Minas Gerais (UFMG, Belo Horizonte) and University of São Paulo (USP, São Paulo) for development of tests for Chagas disease, rubella, herpes simplex viruses 1 and 2, cytomegalovirus; with UFMG for development of technology for macromolecular stabilization (for example, glycoproteins); with Federal University of Porto Alegre (FEPPS) to develop a less expensive TB test kit for public health; and with the University of São Paulo for oxidized low-density lipoprotein, a sensitive marker of cardiac disease |
| Intrials Latin America Clinical Research | Offering a joint post-graduate course on clinical research with the Santa Casa School of Medicine (São Paulo) and the Brazilian Association of Contract Research Organizations (ABRACRO; São Paulo) the Brazilian Association of clinical research organizations. |
| Nortec Química | Collaborations with Cristalia (São Paulo) to develop APIs; ongoing partnership with Farmanguinhos (part of Fiocruz based in Rio de Janeiro) to develop new molecules including antiretrovirals and those for neglected diseases, as well as transfer of technology for production of statins; with Federal University of Rio de Janeiro for consulting services related to chemical synthesis. |
| Pele Nova Biotecnologia | Collaborations with University of São Paulo for pre-clinical animal models for proof of concept and assessment of therapeutic activity of the company's Biomembrane product and with the University of Campinas to test dermatological applications of active protein for cutaneous permeation evaluation. |
| Recepta Biopharma | Funding a laboratory at the Butantan Institute to develop high yielding cell lines for monoclonal antibodies; collaborations with University of São Paulo School of Medicine for immunohistochemical assays; with Sírio Libânes Hospital (São Paulo), Clinical Hospital of University of São Paulo, the Brazilian Institute for Cancer Control (São Paulo), Baleia Hospital (Belo Horizonte), Clinical Hospital of the Federal University of Minas Gerais and the National Cancer Institute (Rio de Janeiro) for conducting clinical research on the company's monoclonal antibodies. Ludwig Institute is both a shareholder and a development partner. |
| Silvestre Labs | Deal with Farmasa (São Paulo) to promote and distribute Dermazine, Dermacerium and GinoDermazine (1% silver sulfadiazine). Collaboration with Federal University of Rio de Janeiro, University of São Paulo, Federal University of São Paulo, UNICAMP for the development and exchange of projects. |
| União Química Farmacêutica Nacional | Joint venture with Aché and Biolab to form COINFAR. Collaboration with Universidade Federal do Rio Grande do Sul (Porto Alegre) for development of nanoparticles and UNIFESP for generics bioequivalence studies. |